Cargando…

Difluprednate 0.05% versus Prednisolone Acetate Post-Phacoemulsification for Inflammation and Pain: An Efficacy and Safety Clinical Trial

BACKGROUND: The purpose of this study was to compare the efficacy and safety of difluprednate 0.05% (PRO-145) versus prednisolone acetate 1% (Prednefrin(®) SF), for management of postoperative inflammation and pain, after cataract surgery. METHODS: This was a Phase III, multicenter, prospective, dou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palacio-Pastrana, Claudia, Chávez-Mondragón, Eduardo, Soto-Gómez, Abraham, Suárez-Velasco, Rubén, Montes-Salcedo, Miguel, Fernández de Ortega, Lourdes, Nasser-Nasser, Linda, Baiza-Durán, Leopoldo, Olvera-Montaño, Oscar, Muñoz-Villegas, Patricia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297453/ https://www.ncbi.nlm.nih.gov/pubmed/32606573 http://dx.doi.org/10.2147/OPTH.S254705

Ejemplares similares

Bioavailability of generic 0.05% difluprednate emulsion in the aqueous humor, cornea, and conjunctiva of New Zealand rabbits after a single dose compared with commercial difluprednate
por: Mercado-Sesma, Arieh, et al.
Publicado: (2017)

Therapeutic Efficacy of Difluprednate 0.05% Versus Prednisolone Acetate 1% in Controlling Inflammation and Macular Oedema Following Phacoemulsification: An Optical Coherence Tomography-Based Study
por: Panda, Bijnya B, et al.
Publicado: (2021)

A retrospective analysis of intraocular pressure changes after cataract surgery with the use of prednisolone acetate 1% versus difluprednate 0.05%
por: Kusne, Yael, et al.
Publicado: (2016)

Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%
por: Stringer, William, et al.
Publicado: (2010)

Difluprednate versus Prednisolone Acetate after Cataract Surgery: a Systematic Review and Meta-Analysis
por: KhalafAllah, Mahmoud Tawfik, et al.
Publicado: (2019)

Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study
por: Wilson, M E, et al.
Publicado: (2016)

Difluprednate ophthalmic emulsion 0.05% (Durezol(®)) administered two times daily for managing ocular inflammation and pain following cataract surgery
por: Smith, Stephen, et al.
Publicado: (2010)

Localized alopecia and suppression of hypothalamic-pituitary-adrenal (HPA) axis in dogs following treatment with difluprednate 0.05% ophthalmic emulsion (Durezol®)
por: Quantz, Katelin, et al.
Publicado: (2021)

Efficacy and safety of bromfenac 0.09% and sodium hyaluronate 0.4% combination therapy, versus placebo in patients with pterygium I–III for clinical signs on ocular inflammation
por: Chávez-Mondragón, Eduardo, et al.
Publicado: (2019)

Evaluation of the Rheological Properties, Preclinical Safety, and Clinical Effectiveness of a New Dispersive Ophthalmic Viscoelastic Device for Cataract Surgery
por: Palacio-Pastrana, Claudia, et al.
Publicado: (2022)

Efficacy and Safety of an Ophthalmic DMPC-Based Nanoemulsion in Patients with Dry Eye Disease: A Phase I/II Randomized Clinical Trial
por: Baiza-Durán, Leopoldo M., et al.
Publicado: (2023)

Topical difluprednate for the treatment of Harada’s disease
por: Onishi, Spencer M, et al.
Publicado: (2015)

A Phase III Randomized Clinical Trial of a 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination, Preservative-Free Ophthalmic Solution vs. 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination in Patients with Controlled Primary Open-Angle Glaucoma
por: Gómez-Aguayo, Francisco, et al.
Publicado: (2018)

Difluprednate for the prevention of ocular inflammation postsurgery: an update
por: Donnenfeld, Eric D
Publicado: (2011)

The role of difluprednate ophthalmic emulsion in clinical practice
por: Jamal, Karim N, et al.
Publicado: (2009)

Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye
por: Park, Chang Hyun, et al.
Publicado: (2019)

Efficacy of 0.05% Chlorhexidine and 0.05% Cetylpyridinium Chloride Mouthwash to Eliminate Living Bacteria on In Situ Collected Biofilms: An In Vitro Study
por: Becker, Kathrin, et al.
Publicado: (2021)

Are Only p-Values Less Than 0.05 Significant? A p-Value Greater Than 0.05 Is Also Significant!
por: Kwak, Sanggyu
Publicado: (2023)

Reexamining Ophthalmic Drugs, Safety and Tolerability in Phase 1 Clinical Trials
por: Muñoz-Villegas, Patricia, et al.
Publicado: (2021)

0.05 - 100 MHz 4 W amplifier
por: Paoluzzi, M
Publicado: (1997)

Halometasone monohydrate (0.05%) in occupational contact dermatitis
por: Maiti, Rituparna, et al.
Publicado: (2016)

Origin of colossal dielectric permittivity of rutile Ti(0.9)In(0.05)Nb(0.05)O(2): single crystal and polycrystalline
por: Song, Yongli, et al.
Publicado: (2016)

Topical difluprednate for the treatment of retinal vasculitis associated with birdshot chorioretinitis
por: Wang, Jay C., et al.
Publicado: (2016)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
por: Baiza-Durán, Leopoldo Martín, et al.
Publicado: (2012)

Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab
por: Muñoz-Villegas, Patricia, et al.
Publicado: (2021)

Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%)
por: Marlowe, Zora T, et al.
Publicado: (2014)

Topical Difluprednate for Early Corneal Graft Rejection After Penetrating Keratoplasty
por: Said, Omar M, et al.
Publicado: (2020)

Delineation of LASIK Flaps with Prednisolone Acetate Eyedrops
por: Fahd, Daoud C, et al.
Publicado: (2014)

Safety and tolerability evaluation after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody (PRO-169) versus ranibizumab in New Zealand white rabbits
por: Baiza-Durán, Leopoldo, et al.
Publicado: (2020)

Comparing The Efficacy Of An Anti-Human VEGF-A Neutralizing Antibody Versus Bevacizumab On A Laser-Induced Choroidal Neovascularization (CNV) Rhesus Monkey Model
por: Olvera-Montaño, Oscar, et al.
Publicado: (2019)

The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery
por: Turan-Vural, Ece, et al.
Publicado: (2011)

Cytomegalovirus retinitis after treatment with topical difluprednate in an aphakic eye of an immunocompetent patient
por: Kaplan, Richard I., et al.
Publicado: (2019)

Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study
por: Molinelli, Elisa, et al.
Publicado: (2020)

The Effect of Topical Cyclosporine 0.05% on Dry Eye after Cataract Surgery
por: Chung, Yeon Woong, et al.
Publicado: (2013)

On the challenges of drawing conclusions from p-values just below 0.05
por: Lakens, Daniël
Publicado: (2015)

Treatment of superficial basal cell carcinoma with ingenol mebutate gel, 0.05%
por: Bettencourt, Miriam S
Publicado: (2016)

The earth is flat (p > 0.05): significance thresholds and the crisis of unreplicable research
por: Amrhein, Valentin, et al.
Publicado: (2017)

The Effect of Topical 0.05% Cyclosporine in the Prevention of Recurrence Following Pterygium Surgery
por: Karadag, Ayse Sevgi, et al.
Publicado: (2021)

Prednisolone-acetate: Increased intraocular pressure: case report
Publicado: (2022)

Validation of a preclinical dry eye model in New Zealand white rabbits during and following topical instillation of 1% ophthalmic atropine sulfate
por: Sánchez‐Ríos, Alejandra, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7t4u8a5c2a6ar4c3bhj5vdug4c